TevaGastrim for Stem Cell Mobilization Sibling Donors

Phase 2 Completed 24 enrolled Sheba Medical Center

NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the efficacy of TevaGastrim which is a biosimilar version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells from normal sibling donors for allogeneic stem cell transplantation.

Timeline

Start: 2012-02
Primary completion: 2016-04
Completion: 2016-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TevaGastrim	Protein / enzyme biologic	10 mg/kg	Subcutaneous

TevaGastrim for Stem Cell Mobilization Sibling Donors

Summary

Timeline

Drugs

Indications